Overview
- Eli Lilly’s Q4 2025 revenue reached $19.3 billion, with Mounjaro at $7.4 billion and Zepbound near $4.3 billion, totaling about $11.7 billion and exceeding 60% of company sales.
- The company forecasts full-year 2026 revenue of $80 billion to $83 billion, implying growth that could approach 27%.
- Lilly holds more than 60% of the U.S. GLP-1 market and trades at a premium valuation near 46 times earnings.
- Competition is intensifying as Novo Nordisk wins approval for an oral Wegovy, and Lilly’s oral candidate orforglipron remains under regulatory review with a planned U.S. launch in Q2 2026.
- Novo projects an adjusted sales decline of 5% to 13% this year and is suing Hims & Hers over compounded products, while head-to-head results reported Zepbound outperforming Wegovy and analysts see the obesity market nearing $100 billion by decade’s end.